Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

Kohada, Yuki; Kaiho, Yasuhiro; Takeda, Kazuya; Kuromoto, Akito; Ito, Jun; Teishima, Jun; Nakamura, Yasuhiro; Kaifu, Tomonori; Nakamura, Akira; Sato, Makoto

doi:10.1002/iju5.12351

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though analysis has shown that ADT may lead to increased infiltration of myeloid-derived suppressor cells (MDSCs) into the TME ( 168 , 169 ), there have been few studies looking at the direct effect of AR signalling on MDSCs or dendritic cells (DCs). B16 and 4T1 implantation results in higher tumour burden in female mice that is correlated with a higher plasmacytoid DC infiltration and less MDSCs compared with male mice ( 170 ).…”

Section: Ar and Cancer Immunotherapymentioning

confidence: 99%

Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor

Zhao,

Wang,

Tan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Across the wide range of clinical conditions, there exists a sex imbalance where biological females are more prone to autoimmune diseases and males to some cancers. These discrepancies are the combinatory consequence of lifestyle and environmental factors such as smoking, alcohol consumption, obesity, and oncogenic viruses, as well as other intrinsic biological traits including sex chromosomes and sex hormones. While the emergence of immuno-oncology (I/O) has revolutionised cancer care, the efficacy across multiple cancers may be limited because of a complex, dynamic interplay between the tumour and its microenvironment (TME). Indeed, sex and gender can also influence the varying effectiveness of I/O. Androgen receptor (AR) plays an important role in tumorigenesis and in shaping the TME. Here, we lay out the epidemiological context of sex disparity in cancer and then review the current literature on how AR signalling contributes to such observation via altered tumour development and immunology. We offer insights into AR-mediated immunosuppressive mechanisms, with the hope of translating preclinical and clinical evidence in gender oncology into improved outcomes in personalised, I/O-based cancer care.

show abstract

Section: Ar and Cancer Immunotherapymentioning

confidence: 99%

Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor

Zhao,

Wang,

Tan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Myeloid-derived suppressor cells (MDSCs) constitute a highly heterogeneous cell population derived from bone marrow. They consist mainly of immature macrophages, dendritic cells, and granulocytes and have immunosuppressive activity (Kohada et al, 2021). MDSCs inhibit T cell activation, prevent dendritic cell maturation, and induce natural killer (NK) cell anergy (Kohada et al, 2021;Koinis et al, 2021).…”

Section: Myeloid-derived Suppressor Cellsmentioning

confidence: 99%

Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer

Zhou

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The tumor microenvironment (TME) is a microecology consisting of tumor and mesenchymal cells and extracellular matrices. The TME plays important regulatory roles in tumor proliferation, invasion, metastasis, and differentiation. Neuroendocrine differentiation (NED) is a mechanism by which castration resistance develops in advanced prostate cancer (PCa). NED is induced after androgen deprivation therapy and neuroendocrine prostate cancer (NEPC) is established finally. NEPC has poor prognosis and short overall survival and is a major cause of death in patients with PCa. Both the cellular and non-cellular components of the TME regulate and induce NEPC formation through various pathways. Insights into the roles of the TME in NEPC evolution, growth, and progression have increased over the past few years. These novel insights will help refine the NEPC formation model and lay the foundation for the discovery of new NEPC therapies targeting the TME.

show abstract

Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

Cited by 2 publications

References 17 publications

Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor

Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor

Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer

Contact Info

Product

Resources

About